Certara/$CERT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Certara
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
Ticker
$CERT
Sector
Primary listing
Industry
Health Care Technology
Headquarters
Employees
1,517
ISIN
US15687V1098
Website
Certara Metrics
BasicAdvanced
$1.9B
-
-$0.02
1.45
-
Price and volume
Market cap
$1.9B
Beta
1.45
52-week high
$16.93
52-week low
$8.64
Average daily volume
1.7M
Financial strength
Current ratio
2.777
Quick ratio
2.644
Long term debt to equity
27.819
Total debt to equity
28.514
Interest coverage (TTM)
1.35%
Profitability
EBITDA (TTM)
98.093
Gross margin (TTM)
60.26%
Net profit margin (TTM)
-0.67%
Operating margin (TTM)
7.07%
Effective tax rate (TTM)
63.58%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
1.12%
Return on equity (TTM)
-0.25%
Valuation
Price to revenue (TTM)
4.654
Price to book
1.7
Price to tangible book (TTM)
-11.86
Price to free cash flow (TTM)
26.121
Free cash flow yield (TTM)
3.83%
Free cash flow per share (TTM)
43.72%
Growth
Revenue change (TTM)
9.37%
Earnings per share change (TTM)
-94.88%
3-year revenue growth (CAGR)
9.44%
3-year earnings per share growth (CAGR)
-39.09%
What the Analysts think about Certara
Analyst ratings (Buy, Hold, Sell) for Certara stock.
Bulls say / Bears say
Barclays upgraded Certara's stock rating from 'Equal Weight' to 'Overweight' and increased the price target to $14.00, citing strong performance and potential acceleration in business performance in the latter half of the year. (Investing.com)
Certara reported preliminary Q1 2025 revenue of $106 million, a 10% year-over-year increase, exceeding analyst expectations and demonstrating robust financial performance. (TradingView News)
The company authorized a $100 million share repurchase program, indicating confidence in its financial health and commitment to returning value to shareholders. (TradingView News)
Barclays downgraded Certara's price target from $13.00 to $11.00, maintaining an 'Equal Weight' rating due to concerns over market uncertainties and potential budget constraints in the life sciences sector. (GuruFocus News)
Leerink Partners reduced their FY2027 earnings per share estimates for Certara, reflecting a weaker outlook for the company's long-term profitability. (ETF Daily News)
Certara's stock experienced significant volatility, with a 22.84% surge following the release of a new version of its Simcyp Simulator, indicating potential instability in investor sentiment. (Finviz)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
Certara Financial Performance
Revenues and expenses
Certara Earnings Performance
Company profitability
Certara News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Certara stock?
Certara (CERT) has a market cap of $1.9B as of June 27, 2025.
What is the P/E ratio for Certara stock?
The price to earnings (P/E) ratio for Certara (CERT) stock is 0 as of June 27, 2025.
Does Certara stock pay dividends?
No, Certara (CERT) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Certara dividend payment date?
Certara (CERT) stock does not pay dividends to its shareholders.
What is the beta indicator for Certara?
Certara (CERT) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.